Canaccord lowered the firm’s price target on Globus Medical (GMED) to $90 from $97 and keeps a Buy rating on the shares. The firm updated its model to reflect the Q2/25 preliminary results which showed revenues in the middle of both the firm’s and the Streets consensus. The company also reaffirmed FY25 revenue to be in the the range of $2.80B-$2.90B and its guidance for EPS to be in the range $3.00-$3.30.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Hold Rating on Globus Medical Amid Management Changes and Spine Business Concerns
- Optimistic Outlook on Globus Medical: Strategic Changes and Positive Q2 Performance Drive Buy Rating
- Globus Medical price target lowered to $88 from $90 at Jefferies
- Roth MKM medical technology analyst holds analyst/industry conference call
- Verizon reports Q2 beat, Block to join S&P 500: Morning Buzz